Universal Birth-Dose Hepatitis B Vaccination Rollback Sparks Major Health Concerns

The decision to scale back universal birth-dose hepatitis B vaccination in the United States is raising serious red flags among public health experts. Two new studies published in JAMA Pediatrics warn that the recent shift in policy by the Centers for Disease Control and Prevention (CDC) could lead to a sharp rise in newborn hepatitis B virus (HBV) infections, additional deaths, and millions of dollars in extra healthcare costs.

The findings serve as a stark reminder that even small adjustments to long-standing immunization strategies can carry significant — and potentially deadly — consequences.

Why Hepatitis B Protection at Birth Matters

HBV remains one of the most serious viral infections that can be transmitted at or shortly after birth. Babies who contract the virus early in life are at extremely high risk of long-term complications. Around 90% of infected newborns go on to develop chronic infections, and roughly a quarter eventually die prematurely from cirrhosis or liver cancer.

Although prenatal screening for HBV has been a routine part of pregnancy care for years, around 12% to 16% of pregnant women in the U.S. are still not screened. That gap leaves a significant number of newborns vulnerable to undetected exposure — and the universal birth-dose vaccination policy was designed precisely to act as a critical safety net.

The Policy Change Causing Concern

In December 2025, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to abandon the universal HBV birth-dose recommendation. Under the new approach, the birth dose is automatically advised only for newborns of HBV-positive or unscreened mothers. For all other infants, vaccination at birth is now subject to “shared clinical decision-making” between parents and providers.

The CDC went on to accept ACIP’s recommendation, despite the change being made without supporting evidence. Many leading pediatricians and major medical organizations have publicly stated they will continue to vaccinate all newborns regardless of the new guidelines.

In addition, the CDC has advised that infants who don’t receive a birth dose should not be vaccinated until they are at least two months old — another change introduced without supporting data.

Study One: Hundreds More Infections Predicted

Researchers at Boston University led the first major study, building a simulation model based on a U.S. birth cohort of 3.7 million infants. Their analysis compared outcomes under both the original universal birth-dose policy and the newly adopted targeted approach.

The findings were sobering. The targeted vaccine recommendation could result in over 600 additional newborn infections, especially in cases where vaccination coverage among infants of unscreened mothers drops to historical lows of around 10%. Even under a more optimistic scenario with 80% coverage, dozens of additional infections would still occur.

To even break even with the previous universal policy, more than 100,000 additional pregnant women would need to be screened in optimistic scenarios — and as many as 400,000 more in worst-case scenarios. Historical data suggests such large screening improvements are unlikely.

Senior author Rachel Epstein, MD, of Boston Medical Center, emphasized that even minor decreases in birth-dose vaccination rates can leave newborns dangerously exposed. According to Epstein, consistency in prevention strategies is essential to safeguarding infants nationwide.

Study Two: Brief Delays Lead to Big Consequences

The second study, led by researchers at Oregon Health & Science University, examined what happens when the HBV birth dose is delayed by anywhere from two months up to 12 years. The simulation focused on 3.6 million infants born to mothers who tested negative for HBV.

The results showed that even short delays in vaccination led to clear increases in infections, hospitalizations, deaths, and healthcare costs. With perfect adherence, delaying the birth dose by just two months would result in:

90 additional acute infections, 76 chronic infections, 29 additional deaths, and around $16.4 million in extra healthcare costs.

If vaccination is delayed all the way to age 12, the projected damage worsens significantly — with 190 more acute infections, 50 additional deaths, and nearly $30 million in added costs. The numbers grow even larger when considering infants whose mothers were unscreened or who did not receive the full vaccination series.

Senior author Noele Nelson, MD, of Cornell University, noted that the model used conservative assumptions and likely underestimates the real-world impact. She also pointed out that the U.S. has a low HBV incidence today specifically because of decades of successful birth-dose vaccination — not because the disease itself is low-risk.

Nelson warned that delaying the first vaccine dose tends to lower the chances that children will complete the recommended vaccination series, potentially reversing years of public health progress.

Why Birth-Dose Vaccination Is So Effective

The HBV vaccine is widely regarded as one of the safest and most effective vaccines available, often providing lifelong protection. Vaccinating babies at birth eliminates the risk of accidental exposure during early childhood, when transmission can occur from family members, caregivers, or community contacts.

By removing a universal recommendation, the new CDC policy adds complexity to a system that previously worked smoothly. Experts warn that this complexity itself is part of the problem.

Implementation Challenges Threaten Progress

In an editorial accompanying the studies, Grace Lee, MD, MPH, of Stanford University, highlighted how the more complicated recommendations may create real-world friction in healthcare settings. According to Lee, when systems are difficult to navigate, the path of least resistance is often to skip the vaccine altogether — even when it isn’t the safest choice.

Lee urged healthcare providers to engage with parents during pregnancy and after birth, framing vaccinations as essential tools to support a healthy childhood. She emphasized that trust is built through respectful communication and consistent guidance — not just from data and modeling.

She also reminded both providers and parents that while modeling offers important glimpses into the future, the real difference is made through everyday implementation.

A Step Backward in Public Health?

The new policy direction has alarmed public health professionals because it threatens to dismantle a system that took decades to build. The success of HBV vaccination in the U.S. is a textbook example of how proactive immunization can transform public health outcomes — preventing infections, saving lives, and reducing the long-term burden on the healthcare system.

The studies make clear that even seemingly small changes — such as delaying a single dose by a few weeks — can ripple outward into significant consequences. With over 600 potential additional newborn infections projected each year, plus the loss of life and millions in healthcare costs, the stakes are far too high to ignore.

The Bigger Picture

The findings come at a time when the U.S. is already struggling with rising vaccine hesitancy, declining trust in public health institutions, and political tension surrounding immunization policy. Reversing universal protections — especially for newborns — risks compounding these challenges and undermining decades of progress against vaccine-preventable diseases.

Many medical societies have already announced that they will continue recommending the universal birth-dose vaccine despite the CDC’s shift, signaling a major divide between national policy and frontline medical practice.

Final Thoughts

The latest research delivers a clear warning: rolling back universal birth-dose hepatitis B vaccination could lead to more sick infants, preventable deaths, and unnecessary healthcare costs. As pediatricians, public health experts, and parents weigh the implications, one truth remains constant — early, consistent vaccination is one of the most powerful tools in protecting newborns from a serious, lifelong disease.

For now, the debate continues, but the science is clear. Universal birth-dose vaccination has saved countless lives, and stepping away from it risks reversing some of the most important public health gains of the past several decades.